Editor’s presentation: Towards a personalised approach in exercise-based cardiovascular rehabilitation: An European Association of Preventive Cardiology (EAPC) call for action
Restricted accessEditorialFirst published online September, 2020
Editor’s presentation: Towards a personalised approach in exercise-based cardiovascular rehabilitation: An European Association of Preventive Cardiology (EAPC) call for action
FardmanABanschickGDRabiaR, et al. Cardiorespiratory fitness and survival following cancer diagnosis. Eur J Prev Cardiol. Epub ahead of print 19 July 2020. DOI: 10.1177/2047487320930873.
2.
DoyleMPIndraratnaPTardoDT, et al.
Safety and efficacy of aerobic exercise commenced early after cardiac surgery: A systematic review and meta-analysis. Eur J Prev Cardiol2019;
26: 36–45.
3.
HarrisonASDohertyP.Does the mode of delivery in routine cardiac rehabilitation have an association with cardiovascular risk factor outcomes?Eur J Prev Cardiol2018;
25: 1925–1933.
4.
PratesiABaldasseroniSBurgisserC, et al.Long-term functional outcomes after cardiac rehabilitation in older patients. Data from the Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active follow-up (CR-AGE EXTRA) randomised study. Eur J Prev Cardiol2019;
26: 1470–1478.
5.
JansenMAPluymenLPDalmeijerGW, et al.Hypertensive disorders of pregnancy and cardiometabolic outcomes in childhood: A systematic review. Eur J Prev Cardiol2019;
26: 1718–1747.
6.
DanchinNAlmahmeedWAl-RasadiK, et al.Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol2018;
25: 1087–1094.
7.
KotsevaKDe BackerGDe BacquerD, et al.Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol2019;
26: 824–835.
8.
EikelboomJWConnollySJBoschJ, et al.;
For the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017;
377: 1319–1330.
9.
PetersohnSPouwelsXRamaekersB, et al. Rivaroxaban plus aspirin for the prevention of ischemic events in patients with cardiovascular disease: A cost-effectiveness study. Eur J Prev Cardiol 2020; 27: 1354–1365.
10.
ZomerESiSHirdTR, et al.Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. Eur J Prev Cardiol2019;
26: 858–868.
11.
KhodnevaYMuntnerPKerteszS, et al.
Prescription opioid use and risk of coronary heart disease, stroke, and cardiovascular death among adults from a prospective cohort (REGARDS study). Pain Med2016;
17: 444–455.
